ARTICLE | Clinical News
Vimizim elosulfase alfa regulatory update
July 28, 2014 7:00 AM UTC
BioMarin said Health Canada approved an NDS for Vimizim elosulfase alfa as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis IVA (MPS IVA, Morquio’...